Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial

S Siva; M Bressel; DG Murphy; M Shaw; S Chander; J Violet; KH Tai; C Udovicich; A Lim; L Selbie; MS Hofman; T Kron; D Moon; J Goad; N Lawrentschuk; F Foroudi

Journal article

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial

S Siva, M Bressel, DG Murphy, M Shaw, S Chander, J Violet, KH Tai, C Udovicich, A Lim, L Selbie, MS Hofman, T Kron, D Moon, J Goad, N Lawrentschuk, F Foroudi

European Urology | ELSEVIER SCIENCE BV | Published : 2018

DOI: 10.1016/j.eururo.2018.06.004

Abstract

Background: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for oligometastatic prostate cancer. However, limited prospective evidence is available. Objective: To determine the safety and feasibility of single fraction SABR for patients with oligometastatic prostate cancer. Secondary endpoints were local and distant progression-free survival (LPFS and DPFS), toxicity, quality of life (QoL), and prostate-specific antigen response. Design, setting, and participants: In a prospective clinical trial, patients were screened with computed tomography, bone scan, and sodium fluoride positron emission tomography scan and had one to three oligometastases. Kaplan-Meier me..

View full abstract

University of Melbourne Researchers

Shankar Siva Author

Mathias Azevedo Bastian Bressel Author

Declan Murphy Author

Sarat Chander Author

Grants

Funding Acknowledgements

The Prostate Cancer Foundation of Australia and the Movember Foundation provided funding for the study. The Peter MacCallum Cancer Centre acted as trial sponsor and assisted with conduct of the study.